Biocept to Present at the 8th Annual LD Micro Invitational Conference on June 5

May. 29, 2018 8:05 am

SAN DIEGO, May 29, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that President and CEO Michael W. Nall is scheduled to present a corporate overview at LD Micro Invitational Conference on Tuesday, June 5, 2018, at 3:30 p.m. Pacific time (6:30 p.m. Eastern time).  The conference is being held at Luxe Sunset Boulevard Hotel in Los Angeles.   


A live webcast of the corporate presentation will be available on the Company's website at  A replay of the presentations will be available for 90 days.

About Biocept

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. Biocept's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit

Cision View original content:

SOURCE Biocept, Inc.

PR Newswire
May 29, 2018 - 8:05 AM EDT

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market